Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.

Currently viewing trials
(Last updated: May 21, 2020)

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 



Hormone Therapy

Radiation Oncology


Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment



Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children


Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence





NEAREST SITE: 1482 miles
Baylor Scott and White University Medical Center

VISITS: Number of visits unavailable


NCT ID: NCT04032080

LY3023414 Followed by Prexasertib in Metastatic Triple Negative Breast Cancer

Pilot Clinical Trial Of Treatment With Oral LY3023414 To Inhibit Homologous Recombination (HR) Followed By Prexasertib In Patients With Chemotherapy-Pretreated Metastatic Triple Negative Breast Cancer (ExIST) Scientific Title

To look at the safety and effects (good and bad) of treating patients with the investigational targeted therapy LY3023414 followed by the investigational targeted therapy prexasertib.
Who is this for?
Women with metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer who have not had more than 3 chemotherapy regimens.    Full eligibility criteria
Contact research site

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3023414, by mouth, twice a day, until disease progression </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">followed by:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy</li> <li class="seamTextUnorderedListItem">Prexasertib, by IV, every 2 weeks</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3023414 is a type of targeted therapy called a PI3K/mTOR inhibitor. </li> <li class="seamTextUnorderedListItem">Prexasertib is a targeted therapy that blocks checkpoint kinase1 (chk1), which plays a role in chemotherapy drug resistance.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04032080' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/prexasertib' target='_blank'>NCI Drug Dictionary: Prexasertib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pi3k-mtor-inhibitor-ly3023414' target='_blank'>NCI Drug Dictionary: LY3023414</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.1064' target='_blank'>Journal of Clinical Oncology: Safety and tolerability of LY3023414 in combination with fulvestrant in treatment refractory advanced breast cancer</a> </li></ul>
See more